Allogene Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Allogene Therapeutics, Inc. filed this Current Report on Form 8-K on November 5, 2019. The filing reports entry into a material definitive agreement and does not provide quarterly or annual operating results.
Material financing agreement
- Allogene entered into a sales agreement with Cowen and Company, LLC as sales agent.
- The agreement permits the company to offer and sell up to $250.0 million of common stock through an at-the-market offering.
- Shares may be sold under the company’s Form S-3 shelf registration statement and related prospectus filed November 5, 2019.
- Allogene is not obligated to sell any shares.
- Cowen may sell shares from time to time based on Allogene’s instructions, including specified price, timing, or size limits.
- The company will pay Cowen a commission of up to 3.0% of aggregate gross proceeds from each sale, reimburse specified legal expenses, and provide customary indemnification and contribution rights.
Financial metrics and liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balance, liquidity, or other operating financial metrics. No proceeds had been reported as raised under the agreement in this filing.
Outlook, risks, and unusual items
- The ATM offering provides potential access to additional capital but could result in dilution to existing common stockholders if shares are sold.
- The amount and timing of any proceeds are uncertain because Allogene controls whether and when shares are sold.
- Cowen or Allogene may terminate the agreement upon notice. Cowen may also terminate in specified circumstances, including a material adverse change that makes marketing the shares or enforcing sale contracts impractical or inadvisable.
- The filing itself is not an offer to sell or a solicitation to buy securities.
Investor verification items
- Verify the full Sales Agreement filed as Exhibit 1.2 to the Form S-3 registration statement.
- Check subsequent SEC filings for shares actually sold, gross proceeds, commissions, and remaining ATM capacity.
- Assess potential dilution based on the number and price of shares issued.
- Review subsequent financial statements for the company’s cash runway, operating losses, financing needs, and use of any ATM proceeds.